787.29
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corporation stock is traded at $787.29, with a volume of 586.24K.
It is down -0.07% in the last 24 hours and up +12.74% over the past month.
McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$787.82
Open:
$787.82
24h Volume:
586.24K
Relative Volume:
0.76
Market Cap:
$97.93B
Revenue:
$377.60B
Net Income/Loss:
$3.35B
P/E Ratio:
31.41
EPS:
25.0619
Net Cash Flow:
$5.67B
1W Performance:
+0.69%
1M Performance:
+12.74%
6M Performance:
+15.36%
1Y Performance:
+54.88%
Mckesson Corporation Stock (MCK) Company Profile
Name
Mckesson Corporation
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MCK
Mckesson Corporation
|
787.29 | 97.99B | 377.60B | 3.35B | 5.67B | 25.06 |
![]()
COR
Cencora Inc
|
328.82 | 63.47B | 316.65B | 1.91B | 1.14B | 9.7209 |
![]()
CAH
Cardinal Health Inc
|
158.68 | 37.36B | 222.58B | 1.57B | 1.85B | 6.4395 |
![]()
HSIC
Henry Schein Inc
|
64.23 | 7.75B | 12.50B | 314.00M | 421.00M | 2.44 |
![]()
AHG
Akso Health Group Adr
|
1.63 | 911.67M | 2.22M | -5.63M | -1.68M | -0.24 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-24 | Resumed | Mizuho | Neutral |
Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Sep-05-24 | Reiterated | Leerink Partners | Outperform |
Aug-08-24 | Reiterated | Mizuho | Neutral |
Feb-26-24 | Initiated | Leerink Partners | Outperform |
Jan-03-24 | Initiated | Barclays | Overweight |
Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
Mar-31-23 | Initiated | Citigroup | Buy |
Aug-22-22 | Resumed | Morgan Stanley | Overweight |
Jul-06-22 | Downgrade | Argus | Buy → Hold |
Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
Apr-01-22 | Resumed | Credit Suisse | Outperform |
Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
Nov-02-21 | Reiterated | Barclays | Overweight |
Nov-02-21 | Reiterated | BofA Securities | Buy |
Nov-02-21 | Reiterated | Evercore ISI | Outperform |
Nov-02-21 | Reiterated | Jefferies | Buy |
Mar-30-21 | Upgrade | Argus | Hold → Buy |
Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
May-15-20 | Upgrade | UBS | Neutral → Buy |
Apr-23-20 | Resumed | Credit Suisse | Neutral |
Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-12-19 | Initiated | Deutsche Bank | Hold |
Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jul-22-19 | Initiated | Guggenheim | Neutral |
Jan-17-19 | Initiated | UBS | Neutral |
Oct-26-18 | Reiterated | Barclays | Equal Weight |
Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
Mar-08-18 | Initiated | Barclays | Equal Weight |
Feb-27-18 | Resumed | BofA/Merrill | Buy |
Feb-02-18 | Reiterated | Mizuho | Neutral |
Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corporation Stock (MCK) Latest News
Will McKesson Corporation stock beat Nasdaq index returnsChart Signals & Safe Entry Point Alerts - newser.com
What machine learning models say about McKesson CorporationJuly 2025 Decliners & Verified Swing Trading Watchlists - newser.com
Can McKesson Corporation stock withstand sector downturnsJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - newser.com
McKesson appeals $152 million Baltimore opioid judgment - Baltimore Sun
Risk vs reward if holding onto McKesson CorporationJuly 2025 Analyst Calls & Long-Term Growth Stock Strategies - newser.com
Is McKesson Corporation stock bottoming out2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com
Is McKesson Corporation stock a momentum leaderFed Meeting & Comprehensive Market Scan Reports - newser.com
What moving averages say about McKesson CorporationJuly 2025 Market Mood & AI Driven Stock Price Forecasts - newser.com
What MACD trends signal for McKesson Corporation (MCK) stockTrade Risk Report & Free Long-Term Investment Growth Plans - newser.com
Chart overlay techniques for tracking McKesson CorporationMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Tools to monitor McKesson Corporation recovery probabilityEarnings Miss & AI Driven Stock Price Forecasts - newser.com
Why McKesson Corporation stock remains stableJuly 2025 Highlights & Real-Time Volume Analysis - newser.com
Analyzing drawdowns of McKesson Corporation with statistical toolsJuly 2025 Breakouts & Weekly Watchlist of Top Performers - newser.com
Why McKesson Corporation (MCK) stock stays on buy listsPortfolio Risk Summary & High Conviction Buy Zone Alerts - nchmf.gov.vn
Will McKesson Corporation stock gain from green policies2025 Dividend Review & Long-Term Growth Portfolio Plans - newser.com
Citius Oncology adds McKesson as distributor for lymphoma therapy - Investing.com
Citius Oncology signs U.S. distribution agreement with McKesson to support Lymphir commercial launch - MarketScreener
Citius Oncology Signs U.S. Distribution Agreement With Mckesson To Support Lymphir Commercial Launch - TradingView
Can McKesson Corporation stock maintain growth trajectory2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch - PR Newswire
Chart based exit strategy for McKesson Corporation2025 Price Momentum & Low Risk Entry Point Guides - newser.com
McKesson Corporation (MCK) Stock Analysis: Unveiling Growth Potential with a 6.45% Upside - DirectorsTalk Interviews
Relative strength of McKesson Corporation in sector analysis2025 Price Targets & Weekly High Momentum Picks - newser.com
Why McKesson Corporation (MCK) stock attracts wealthy investors2025 Support & Resistance & Verified Short-Term Trading Plans - newser.com
Sector ETF performance correlation with McKesson Corporation2025 Institutional Moves & Growth Focused Entry Point Reports - newser.com
McKesson Corporation stock daily chart insightsJuly 2025 Analyst Calls & Proven Capital Preservation Methods - newser.com
How McKesson’s (MCK) Exclusive PHYRAGO Distribution Could Shape Its Specialty Pharma Growth Trajectory - Yahoo Finance
Can McKesson Corporation stock continue upward trendJuly 2025 Update & Verified Entry Point Signals - nchmf.gov.vn
Buybacks Report: Why McKesson Corporation (MCK) stock attracts wealthy investors2025 Pullback Review & Consistent Income Trade Recommendations - nchmf.gov.vn
How McKesson Corporation stock benefits from tech adoption2025 Biggest Moves & High Accuracy Trade Alerts - nchmf.gov.vn
McKesson (MCK): Evaluating Valuation After Launching PHYRAGO Oncology Partnership - simplywall.st
Portfolio Update: Why McKesson Corporation (MCK) stock attracts wealthy investors2025 Earnings Impact & Fast Moving Market Watchlists - nchmf.gov.vn
Published on: 2025-10-17 22:21:17 - newser.com
MCKESSON CORPORATION (MCK) - MSN
McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
Mckesson Corporation Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):